Frank Karbe - Better Therapeutics Interim CEO
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
CEO
Frank Karbe is Interim CEO of Better Therapeutics
| Age | 56 |
| Phone | 415 887 2311 |
| Web | https://www.bettertx.com |
Frank Karbe Latest Insider Activity
Tracking and analyzing the buying and selling activities of Frank Karbe against Better Therapeutics otc stock is an integral part of due diligence when investing in Better Therapeutics. Frank Karbe insider activity provides valuable insight into whether Better Therapeutics is net buyers or sellers over its current business cycle. Note, Better Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Better Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Frank Karbe over a year ago Purchase by Frank Karbe of 137005 shares of Better Therapeutics | ||
Frank Karbe over a year ago Purchase by Frank Karbe of 242424 shares of Better Therapeutics |
Better Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9505) % which means that it has lost $0.9505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.2164) %, meaning that it created substantial loss on money invested by shareholders. Better Therapeutics' management efficiency ratios could be used to measure how well Better Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Better Therapeutics currently holds 14.88 M in liabilities with Debt to Equity (D/E) ratio of 0.81, which is about average as compared to similar companies. Better Therapeutics has a current ratio of 5.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Better Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Better Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Better Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Better to invest in growth at high rates of return. When we think about Better Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 11 records | CEO Age | ||
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Malte MD | Hookipa Pharma | 62 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Paul Wagner | Forte Biosciences | 54 | |
| Shane PharmD | Cingulate | 49 | |
| Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
| Daniel MBA | Acumen Pharmaceuticals | 54 | |
| Nevan JD | Rezolute | 57 | |
| Tiago MD | Pasithea Therapeutics Corp | 47 | |
| Milton Werner | Inhibikase Therapeutics | 60 | |
| PharmD PharmD | Cingulate | 49 | |
Management Performance
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 |
Better Therapeutics Leadership Team
Elected by the shareholders, the Better Therapeutics' board of directors comprises two types of representatives: Better Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Better. The board's role is to monitor Better Therapeutics' management team and ensure that shareholders' interests are well served. Better Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Better Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Interim CEO | ||
| Thiago Oliveira, Chief Officer | ||
| Angela Willis, Senior Access | ||
| Kevin Appelbaum, CoFounder Director | ||
| Jessica Meng, Chief Officer | ||
| Mark MD, Chief Officer | ||
| Mark Heinen, Head CFO | ||
| Kristin Wynholds, Chief Officer | ||
| Leslie Miller, Controller | ||
| Andres Camacho, Senior Engineering | ||
| David MBA, CoFounder Chairman | ||
| Diane GomezThinnes, Chief Officer |
Better Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Better Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 8.83 M | ||||
| Shares Outstanding | 54.52 M | ||||
| Shares Owned By Insiders | 53.41 % | ||||
| Shares Owned By Institutions | 2.94 % | ||||
| Number Of Shares Shorted | 2.13 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 49,559 X | ||||
| Gross Profit | (674 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |